Sign in

    Jennifer Kim

    Research Analyst at Cantor Fitzgerald

    Jennifer Kim is an Equity Research Analyst at Cantor Fitzgerald, specializing in equity research with analytical coverage in areas such as healthcare and biotechnology. She has contributed stock ratings on multiple companies and sectors, with a growing research record, though exact performance metrics and detailed ranking data are not publicly reported. Jennifer began her analyst career following positions at Rosenblatt Securities and HC Wainwright, and previously worked at the Reyna Laboratory for Rational Decision Making and Cornell University’s Office of Labor Education Research before joining Cantor Fitzgerald. Her academic background and roles reflect strong analytical expertise, though professional licenses or FINRA registrations have not been confirmed in the publicly available information.

    Jennifer Kim's questions to BELITE BIO (BLTE) leadership

    Jennifer Kim's questions to BELITE BIO (BLTE) leadership • Q2 2025

    Question

    Jennifer Kim of Cantor Fitzgerald asked for the specific timing and nature of the DRAGON trial data release after its Q4 completion and the efficacy metrics needed for filing. She also questioned the latest dropout rate in the PHOENIX trial and the expected depth of its interim analysis.

    Answer

    CFO & Director Hao-Yuan Chuang explained that for the DRAGON trial, they aim to show a statistically significant difference in atrophic lesion growth rate, similar to approved GA drugs. For the PHOENIX trial, he stated the dropout rate is within the expected range and the design of the interim analysis has not yet been finalized.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to BELITE BIO (BLTE) leadership • Q1 2025

    Question

    Jennifer Kim from Cantor Fitzgerald inquired about recent FDA interactions, any perceived regulatory risks from agency changes, and the efficacy and safety goals for the upcoming 24-month Phase III DRAGON trial data.

    Answer

    Chairman and CEO Dr. Tom Lin confirmed a meeting with the FDA has been scheduled and expressed no concern over regulatory risk from personnel changes. Chief Scientific Officer Dr. Nathan Mata elaborated on the DRAGON trial, stating it is powered to detect a 35% treatment effect. He highlighted the positive safety outlook, referencing the interim analysis which showed a low overall withdrawal rate of less than 10% and only 3.8% due to ocular adverse events.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to BELITE BIO (BLTE) leadership • Q4 2024

    Question

    Jennifer Kim of Cantor Fitzgerald inquired about the potential outcomes of engaging with ex-U.S. regulatory authorities following the DSMB's recommendation for Stargardt disease. She also asked for the rationale behind increasing the PHOENIX trial's sample size for Geographic Atrophy (GA) and how the trial's interim analysis will inform the decision to start a second GA study.

    Answer

    Chairman and CEO Dr. Tom Lin responded, expressing confidence that international regulators would likely align with the positive DSMB recommendation but affirmed the study would proceed as planned regardless. For the GA trial, Dr. Lin explained the sample size was increased to 'boost our chances of success' due to smooth enrollment, noting that positive interim results would expedite the launch of a second Phase III trial for GA.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to BELITE BIO (BLTE) leadership • Q3 2024

    Question

    Jennifer Kim asked for an update on the PHOENIX trial's discontinuation rates, the remaining steps for the DRAGON trial's interim analysis, and the enrollment status of the DRAGON 2 trial.

    Answer

    Chief Scientific Officer Nathan L. Mata stated the all-cause discontinuation rate in the PHOENIX trial is around 15%. He and executive Tom Lin explained that the DRAGON interim analysis is pending data cleaning and a DSMB meeting, which is contingent on appointing a new chair, with results expected by late 2024 or early 2025. For DRAGON 2, enrollment is underway and expected to be complete by Q2 of the following year.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to CATALYST PHARMACEUTICALS (CPRX) leadership

    Jennifer Kim's questions to CATALYST PHARMACEUTICALS (CPRX) leadership • Q2 2025

    Question

    Jennifer Kim asked for details on Firdapse's average dose and discontinuation rates in the quarter. She also inquired about Fycompa's generic competition, specifically Teva's exclusivity period, and whether the full-year guidance for the product might be conservative.

    Answer

    EVP & CCO Jeff Del Carmen reported that Firdapse's annual discontinuation rate was below 20% and the average daily dose increased by approximately 4mg, as expected. President & CEO Richard Daly confirmed Teva has 180-day exclusivity but explained the Fycompa guidance is a prudent position, accounting for the risk of additional generic competitors and channel loading later in the year.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to INSMED (INSM) leadership

    Jennifer Kim's questions to INSMED (INSM) leadership • Q2 2025

    Question

    Jennifer Kim asked about market access for brensocatib, focusing on the reauthorization process and the potential impact of the Medicare out-of-pocket max reset on launch dynamics between Q4 2025 and Q1 2026.

    Answer

    CEO William Lewis stated that reauthorization is a key part of payer negotiations aimed at a 'frictionless' process. COO Roger Adsett addressed the Medicare dynamics, noting Q4 is advantageous as patients have likely met their co-pay burden. He acknowledged the Q1 reset is a historical challenge but expressed hope that the process will be smoother in the second year of the new rules, with Insmed ready to provide patient support.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to INSMED (INSM) leadership • Q1 2025

    Question

    Jennifer Kim asked for the timing of the planned U.S. manufacturing expansion for Brensocatib and for an update on the blinded data trends from the BiRCh and ENCORE trials.

    Answer

    CEO William Lewis noted the U.S. manufacturing plan has been underway for some time as part of a tariff mitigation strategy, with more updates to come. CMO Martina Flammer added that blinded data from the ENCORE trial looks consistent with the successful ARISE study, and in the BiRCh trial, key PROs are trending in the right direction.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to INSMED (INSM) leadership • Q1 2025

    Question

    Jennifer Kim inquired about the timing for expanding the U.S. manufacturing footprint for Brensocatib and asked for an update on the blinded data from the BiRCh and ENCORE trials.

    Answer

    CEO William Lewis explained that the plan to establish a second U.S. manufacturing source for Brensocatib has been underway for some time, but did not provide a specific timeline. CMO Martina Flammer added that for the ENCORE trial, blinded PRO data trends look consistent with the successful ARISE study. For the BiRCh trial, both primary and secondary PROs are trending in the right direction.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to INSMED (INSM) leadership • Q4 2024

    Question

    Jennifer Kim asked about the expected placebo rate and variability in the 24-week CRS trial and questioned the importance of the 6-minute walk endpoint in the Phase II TPIP study.

    Answer

    CMO Martina Flammer cited placebo rates from comparable studies ranging from 0.2 to 1.5 point reductions. CEO Will Lewis added that for both the CRS and TPIP Phase II studies, the goal is to see a clear directional signal, with statistical significance being less critical than informing a Phase III design. For TPIP, they noted the 6-minute walk is a key FDA endpoint but is highly variable, so they hope for a directional improvement over 20 meters.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to INSMED (INSM) leadership • Q3 2024

    Question

    Jennifer Kim from Cantor Fitzgerald asked about the remaining steps for the brensocatib filing, confidence in receiving priority review, and the potential impact of a mid-year launch on revenue models. She also requested an update on the number of patients still in screening for the ARIKAYCE ENCORE study.

    Answer

    CEO Will Lewis confirmed the brensocatib filing is on track for Q4, with a decision on priority review expected by day 74 post-filing, which would dictate a mid-year or late-year launch. CFO Sara Bonstein acknowledged that the timing of a launch within a quarter is an important factor for financial modeling. CMO Martina Flammer added that about 40-45 patients are still in the screening period for the ENCORE study, with an expected 15-20 to be randomized.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to INSMED (INSM) leadership • Q3 2024

    Question

    Jennifer Kim asked about the remaining steps for the brensocatib filing, the likelihood of receiving priority review, and the number of patients remaining in screening for the ARIKAYCE ENCORE study.

    Answer

    CEO Will Lewis confirmed a Q4 filing for brensocatib is on track, with an FDA decision on priority review expected in Q1 2025, which would dictate a mid-year launch. CFO Sara Bonstein noted launch timing would impact revenue models. CMO Martina Flammer clarified that for the ENCORE study, an additional 40-45 patients are in screening, with 15-20 expected to be randomized.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to EyePoint Pharmaceuticals (EYPT) leadership

    Jennifer Kim's questions to EyePoint Pharmaceuticals (EYPT) leadership • Q2 2025

    Question

    Jennifer Kim asked about EyePoint's policy on disclosing masked data from the Phase 3 trials, the potential for introducing operational bias, and if there will be a regular cadence for safety updates.

    Answer

    CEO Dr. Jay Duker explained that while high-level masked demographics might be shared, the company will not release data that could introduce bias into the ongoing trials. He confirmed that periodic safety updates, based on feedback from the independent Data Safety Monitoring Committee (DSMC), are likely. CMO Dr. Ramiro Ribeiro reinforced the goal of not introducing unnecessary bias into a well-run study.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to EyePoint Pharmaceuticals (EYPT) leadership • Q2 2025

    Question

    Jennifer Kim from Cantor Fitzgerald asked about the company's policy on disclosing masked Phase 3 data, the potential for introducing operational bias, and whether to expect a regular cadence of safety updates.

    Answer

    CEO Jay Duker explained that while high-level masked demographics might be shared, the company will avoid releasing data that could introduce bias into the well-running trials. CMO Ramiro Ribeiro added that an independent data monitoring committee assesses safety. Regarding future updates, Duker confirmed it is 'quite likely' that periodic safety updates will be provided as the company hears from the Data Safety Monitoring Committee.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to EyePoint Pharmaceuticals (EYPT) leadership • Q1 2025

    Question

    Jennifer Kim inquired about the pace of Phase III enrollment for DURAVYU, asking if it might complete earlier than guided, and also requested details on the upcoming FDA meeting for the Diabetic Macular Edema (DME) indication.

    Answer

    President and CEO Dr. Jay Duker confirmed the official guidance for completing enrollment in H2 2025 but acknowledged that the LUGANO trial could potentially finish enrollment in Q2 2025. Chief Medical Officer Dr. Ramiro Ribeiro added that for the DME indication, the company will propose a single Phase III study versus standard-of-care to the FDA, with a meeting expected by the summer.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to EyePoint Pharmaceuticals (EYPT) leadership • Q1 2025

    Question

    Jennifer Kim of Cantor Fitzgerald inquired about the rapid pace of Phase III enrollment for DURAVYU, asking if it could complete earlier than guided, and also requested details on the upcoming FDA meeting for the Diabetic Macular Edema (DME) indication.

    Answer

    President and CEO Dr. Jay Duker acknowledged that based on current trends, enrollment for the LUGANO trial could potentially complete in Q2 2025, though official guidance remains for the second half of 2025. Chief Medical Officer Dr. Ramiro Ribeiro added that for the DME indication, the company plans to propose a single, efficient Phase III study to the FDA with BCVA as the primary endpoint, with the meeting expected by summer.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to EyePoint Pharmaceuticals (EYPT) leadership • Q4 2024

    Question

    Jennifer Kim sought more details on the planned regulatory meetings for the DME program, including timing for an update, and asked what factors would trigger the decision to advance the DME pivotal program.

    Answer

    President and CEO Dr. Jay Duker confirmed a public update would follow receipt of written minutes from the agencies. He stressed that the wet AMD program is the absolute priority, and any decision on the DME program's timing is secondary to ensuring the success and financial runway for the wet AMD trials.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to PRECIGEN (PGEN) leadership

    Jennifer Kim's questions to PRECIGEN (PGEN) leadership • Q2 2024

    Question

    Jennifer Kim asked about the expected pace of enrollment for the PRGN-2012 confirmatory trial and questioned CCO Phil Tennant about his plans for ex-U.S. markets and monetization strategies, given his global experience.

    Answer

    President and CEO Dr. Helen Sabzevari expressed confidence in a 'fast' enrollment pace for the confirmatory trial, citing the rapid enrollment of prior studies even during COVID and the heightened patient interest following strong ASCO data. Chief Commercial Officer Phil Tennant confirmed the company has 'global ambition' for PRGN-2012, actively assessing ex-U.S. opportunities where a significant disease burden persists despite HPV vaccination programs.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to PRECIGEN (PGEN) leadership • Q2 2024

    Question

    Jennifer Kim asked about the expected pace of enrollment for the confirmatory trial and whether new CCO Phil Tennant is exploring ex-U.S. commercialization strategies for PRGN-2012.

    Answer

    President and CEO Dr. Helen Sabzevari expressed confidence in a rapid enrollment pace for the confirmatory trial, citing strong patient interest following the ASCO data presentation and the fast enrollment of prior trials. Chief Commercial Officer Phil Tennant confirmed the company has global ambitions for the drug and is actively assessing ex-U.S. market opportunities, noting a significant commercial opportunity remains despite HPV vaccine programs in some countries.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to PRECIGEN (PGEN) leadership • Q2 2024

    Question

    Jennifer Kim asked about the expected pace of enrollment for the PRGN-2012 confirmatory trial and whether new CCO Phil Tennant is exploring global development and monetization strategies for the asset.

    Answer

    President and CEO Dr. Helen Sabzevari responded that based on rapid past enrollment and significant patient interest following the ASCO presentation, they anticipate a fast enrollment pace for the confirmatory trial. Chief Commercial Officer Phil Tennant confirmed the company has global ambitions for PRGN-2012, noting a significant commercial opportunity exists ex-U.S. and that they are actively assessing these markets.

    Ask Fintool Equity Research AI

    Jennifer Kim's questions to PRECIGEN (PGEN) leadership • Q4 2023

    Question

    Inquired about the venue for the upcoming Phase II data presentation, commercial manufacturing readiness, and the decision process for adding a repeat dosing arm to the PRGN-2012 study.

    Answer

    The company is still deciding on the venue for the Phase II data presentation and will provide guidance soon. The commercial manufacturing facility is on track and will have sufficient capacity for launch. The decision to add a repeat dosing arm is not dependent on further data, as it's an optional addition to the already-agreed-upon confirmatory trial design to potentially expand the label.

    Ask Fintool Equity Research AI